Airway-to-biophase transfer of inhaled oligonucleotides

Advanced Drug Delivery Reviews

Volumn 19, Issue 1, 1996, Pages 47-71

  Wu Pong, Susanna ^a   Byron, Peter R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Absorption; Aerosol; Airway to biophase transfer; Immunomodulator; Inhalation dosimetry; Inhaler; Lung clearance; Macromolecule; Oligonucleotide; Pulmonary delivery; Receptor; Transcription suppression

Indexed keywords

ABSORPTION; AEROSOLS; CYTOLOGY; DOSIMETRY; MACROMOLECULES; METABOLISM; PROTEINS; PULMONARY DISEASES; RESPIRATORY THERAPY; TISSUE;

AIRWAY TO BIOPHASE TRANSFER; CELL BIOLOGY; IMMUNOMODULATOR; INHALER; OLIGONUCLEOTIDES; PEPTIDES; PULMONARY DELIVERY; RECEPTOR; RESPIRATORY TRACT; TRANSCRIPTION SUPPRESSION;

DRUG THERAPY;

ANTISENSE OLIGONUCLEOTIDE; ARACHIDONATE 5 LIPOXYGENASE; ASPARTIC ACID DERIVATIVE; CYTOKINE RECEPTOR; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; GENE PRODUCT; IMMUNOMODULATING AGENT; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INULIN; LEUKOTRIENE C4; OLIGONUCLEOTIDE; PHOSPHOROTHIOIC ACID DERIVATIVE; TRANSCRIPTION FACTOR; TRIMETHYLAMMONIUM SALT DERIVATIVE;

AEROSOL; ASTHMA; BRONCHIECTASIS; BRONCHOSPASM; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONDYLOMA; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSE; DRUG MECHANISM; DRUG POTENCY; DRUG STABILITY; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRADERMAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG EMPHYSEMA; MACROMOLECULE; MOLECULAR SIZE; NEBULIZER; NONHUMAN; PNEUMONIA; POWDER; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; RESPIRATORY TRACT INFECTION; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0342902407     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-409X(95)00099-S     Document Type: Review

References (140)

1. Wasserman, M.A. and Renzetti, L.M. (1994) Therapeutic targets in lung disease - the state of the art. In: P.R. Byron, R.N. Dalby and S.J. Farr (Eds), Proceedings of Respiratory Drug Delivery IV, Richmond VA, Interpharm Press, Buffalo Grove, IL, pp.1-10.
2. Byron, P.R. and Patton, J.S. (1994) Drug delivery via the respiratory tract. J. Aerosol Med. 7, 49-75.
3. Byron, P.R., Miller, N.C., Blondino, F.E., Visich, J.E. and Ward, G.H. (1994) Some aspects of alternative propellant solvency. Proceedings of Respiratory Drug Delivery IV, Richmond VA, In: P.R. Byron, R.N. Dalby and S.J. Farr (Eds), Interpharm Press, Buffalo Grove, IL, pp. 231-242.
4. Hindle, M. and Byron, P.R. (1995) Dose emissions from marketed dry powder inhalers. Int. J. Pharm. 116, 169-177.
5. Zierenberg, B. (1992) The Respimat, a new inhalation system based on the piezoelectric effect. J. Biopharm. Sci. 3, 85-92.
6. Wu-Pong, S. (1994) Oligonucleotides: opportunities for drug therapy and research. Pharm. Tech. 18, 102-112.
7. Maher, L.J., III, Wold, B. and Dervan, P.B. (1989) Inhibition of DNA binding proteins by oligonucleotide-directed triple helix formation. Science 245, 725-730.
8. Beat, P.A. and Dervan, P.B. (1991) Second structural motif for recognition of DNA by oligonucleotide-directed triple-helix formation. Science 251, 1360-1366.
9. Orson, F.M., Thomas, D.W., McShan, W.M., Kessler, D.J. and Hogan, M.E. (1991) Oligonucleotide inhibition of IL2R-alpha mRNA transcription by promoter region collinear triplex formation in lymphocytes. Nucl. Acids Res. 19, 3435-3441.
10. Postel, E.H., Flint, S.J., Kessler, D.J. and Hogan, M.E. (1991) Evidence that a triplex-forming oligodeoxyribonucleotide binds to the c-myc promoter in HeLa cells, thereby reducing c-myc mRNA levels. Proc. Natl. Acad. Sci. USA 88, 8227-8231.
11. Ing, N.H., Beekman, J.M., Kessler, D.J., Murphy, M., Jayaraman, K., Zendegui, J.G., Hogan, M.E., O'Malley, B.W. and Tsai, M.J. (1993) In vivo transcription of a progesterone-response gene is specifically inhibited by a triplex-forming oligonucleotide. Nucl. Acids Res. 21, 2789-2796.
12. Bielinska, A., Shivdasani, R.A., Zhang, L. and Nabel, G.J. (1990) Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. Science 250, 997-1000.
13. Coleman, J., Green, P.J. and Inouye, M. (1984) Use of RNAs complementary to specific mRNAs to regulate the expression of individual bacterial genes. Cell 37, 429-436.
14. Melton, D.A. (1985) Injected antisense RNAs specifically block mRNA translation in vivo, Proc. Natl. Acad. Sci. USA 82, 144-148.
15. Smith, C.C., Aurelian, L., Reddy, M.P., Miller, P.S. and Tso, P.O.P. (1986) Antiviral effect of an oligo(nucleoside methylphosphonates) complementary to the splice junction of herpes simplex virus-type I immediate early pre-mRNAs 4 and 5. Proc. Natl. Acad. Sci. USA 83, 2787-2791.
16. Haeptle, M.T., Frank, R. and Dobberstein, B. (1986) Translation arrest by oligodeoxynucleotides complementary to mRNA coding sequences yields polypeptides of predetermined length. Nucl. Acids Res. 14, 1427-1448.
17. Strickland, S., Huarte, J., Belin, D., Vassalli, A., Rickels, R.J. and Vassalli, J.D. (1988) Antisense RNA directed against the 3′ noncoding region prevents dormant mRNA activation in mouse oocytes. Science 241, 680-684.
18. Minshull, J. and Hunt, T. (1986) The use of single-stranded DNA and RNase H to promote quantitative 'hybrid arrest of translation' of mRNA/DNA hybrids in reticulocyte lysate cell-free translation. Nucl. Acids Res. 14, 6433-6451.
19. Walder, R.Y. and Walder, J.A. (1988) Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA 85, 5011-5015.
20. Cazenave, C., Chevrier, M., Thuong, N.T. and Helene, C. (1987) Rate of degradation of [alpha]- and [β]-oligodeoxynucleotides in Xenopus oocytes. Implications for anti-messenger strategies. Nucl. Acids Res. 15, 10507-10521.
21. Brody, S.L. and Crystal, R.G. (1994) Adenovirus-mediated in vivo gene transfer. Ann. N.Y. Acad. Sci. 716, 90-101.
22. Miller, A.D. (1990) Retrovirus packaging cells. Hum. Gene Ther. 1, 5-14.
23. Rosenfeld, M.A., Yoshimura, K., Trapnell, B.C., Yoneyama, K., Rosenthal, E.R., Dalemans, W., Fukayama, M., Bargon, J., Stier, L.E., Stratford-Perricaudet, L., Perricaudet, M., Guggino, W.B., Pavirani, A., Lecocq, J.P. and Crystal, R.G. (1991) In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68, 143-155.
24. Tuerk, C. and Gold, L. (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249, 505-510.
25. Blackwell, T.K. and Weintraub, H. (1990) Differences and similarities in DNA-binding preferences of myoD and E2A protein complexes revealed by binding site selection. Science 250, 1104-1110.
26. Bock, L.C., Griffin, L.C., Latham, J.A., Vermaas, E.H. and Toole, J.J. (1992) Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 355, 564-566.
27. Murzin, A.G. (1993) OB(oligonucleotide/oligosaccharide binding)-fold: common structural and functional solution for non-homologous sequences. EMBO J. 12, 861-867.
28. Kitajama, I., Shinohara, T., Bilakovics, J., Brown, D.A., Xu, X. and Nerenberg, M. (1992) Ablation of transplanted HTLV-1 tax-transformed tumors in mice by antisense inhibition of NF-kB. Science 258, 1729-1795.
29. Burch, R.M. and Mahan, L.C. (1991) Oligonucleotides antisense to the interleukin 1 receptor mRNA block the effects of interleukin 1 in cultured murine and human fibroblasts and in mice. J. Clin. Invest. 88, 1190-1196.
30. Skorski, T., Nieborowska-Skorska, M., Nicolaides, N.C., Szczylik, C., Iversen, P., Iozzo, R.V., Zon, G. and Calabretta, B. (1994) Suppression of Philadelphia leukemia cell growth in mice by bcr-abl antisense oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA 91, 4504-4508.
31. Dean, N.M., McKay, R., Condon, T.P. and Bennett, C.F. (1994) Inhibition of protein kinase C-a expression in human A549 cells by antisense oligonucleotide inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J. Biol. Chem. 269, 16416-16424.
32. Wahlestedt, C., Golanov, E., Yamamoto, S., Yee, F., Ericson, H., Yoo, H., Inturrisi, C.E. and Reis, D.J. (1993) Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischaemic infarctions. Nature 363, 260-263.
33. Wahlestedt, C., Pich, E.M., Koob, G.F., Yee, F. and Heilig, M. (1993) Modulation of anxiety and neuropeptide Y-Y1+ receptors by antisense oligodeoxynucleotides. Science 259, 528-530.
34. Zhang, M. and Creese, I. (1993) Antisense oligodeoxynucleotide reduces brain dopamine D2 receptors: behavioral correlates. Neurosci. Lett. 161, 223-226.
35. Morishita, R., Gibbons, G.H., Ellison, K.E., Nakajima, M., Zhang, L., Kaneda, Y., Ogihara, T. and Dzau, V.J. (1993) Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc. Natl. Acad. Sci. USA 90, 8474-8478.
36. Simons, M., Edelman, E.R., DeKeyser, J.L., Lanter, R. and Rosenberg, R.D. (1992) Antisense c-myb oligonucleotides inhibit intimai arterial smooth muscle cell accumulation in vivo. Nature 359, 67-70.
37. Freier, S.M. (1993) Hybridization: considerations affecting antisense drugs. In: S.T. Crooke and B. Lebleu (Eds), Antisense Research and Applications, CRC Press, Boca Raton, FL, pp. 67-82.
38. Matsukura, M., Shinozuka, K., Zon, G., Mitsuya, H., Reitz, M., Cohen, J.S. and Broder, S. (1987) Phosphorothioate analogs of oligodeoxynucleotides: Inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 84, 7706-7710.
39. Galbraith, W.M., Hobson, W.C., Giclas, P.C., Schechter, P.J. and Agrawal, S. (1994) Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Dev. 4, 201-207.
40. Cornish, K.G., Iversen, P., Smith, L., Arneson, M. and Bayever, E. (1993) Cardiovascular effects of a phosphorothioate oligonucleotide with sequence antisense to p53 in the conscious rhesus monkey. Pharmacol. Commun. 3, 239-247.
41. Crooke, R. (1993) In vitro and in vivo toxicology of first generation analogs. In: S.T. Crooke and B. Lebleu (Eds), Antisense Research and Applications, CRC Press, Boca Raton, FL, pp. 471-492.
42. Arm, J.P. and Lee, T.H. (1992) The pathobiology of bronchial asthma. Adv. Immunol. 51, 323-382.
43. Seale, D.D. and Beaver, B.M. (1992) Pathophysiology of lung cancer. Nurs. Clin. N. Am. 27, 603-613.
44. Kalemkerian, G.P. (1994) Biology of lung cancer. Curr. Opin. Oncol. 6, 147-155.
45. Yu, H. and Schultz, R.M. (1990) Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. Cancer Res. 50, 7623-7633.
46. Tanaka, Y., Tang, X., Hou, D.X., Gao, H., Ktabayashi, I., Gachelin, G. and Yokoyama, K. (1992) Phenotypic conversion of SV40-immortalized human diploid fibroblasts to senescing cells by introduction of an antisense gene for SV40-T antigen. Cell Struct. Func. 17, 351-362.
47. Mukhopadhyay, T., Tainsky, M., Cavender, A.C. and Roth, J. A. (1991) Specific inhibition of k-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res. 51, 1744-1748.
48. Georges, R.N., Mukhopadhyay, T., Zhang, Y., Yen, N. and Roth, J.A. (1993) Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense k-ras construct. Cancer Res. 53, 1743-1746.
49. Zhang, Y., Mukhopadhyay, T., Donehower, L.A., Georges, R.N. and Roth, J.A. (1993) Retroviral vector-mediated transduction of k-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Hum. Gene Ther. 4, 451-460.
50. Strauss, M., Hering, S., Lieber, A., Herrmann, G., Griffin, B.E. and Arnold, W. (1992) Stimulation of cell division and fibroblast focus formation by antisense repression of retinoblastoma protein synthesis. Oncogene 7, 769-773.
51. Mukhopadhyay, T. and Roth, J.A. (1993) A codon 248 p53 mutation retains tumor suppressor function as shown by enhancement of tumor growth by antisense p53. Cancer Res. 53, 4362-4366.
52. Chiang, M.Y., Chan, H., Zounes, M.A., Freier, S.M., Lima, W.F. and Bennett, C.F. (1991) Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J. Biol. Chem. 266, 18162-18171.
53. Wickstrom, E. (1986) Oligodeoxynucleotide stability in subcellular extracts and culture media. J. Biochem. Biophys. Methods 13, 97-102.
54. Eder, P.S., DeVine, R.J., Dagle, J.M. and, Walder, J.A. (1991) Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3' exonuclease in plasma. Antisense Res. Dev. 1, 141-151.
55. Sands, H., Gorey-Feret, L.J., Cocuzza, A.J., Hobbs, F.W., Chidester, D. and Trainor, G.L. (1994) Biodistribution and metabolism of internally H-labeled oligonucleotides. 1. Comparison of a phosphodiester and a phosphorothioate. Mol. Pharmacol. 45, 932-943.
56. Cossum, P.A., Sasmor, H., Dellinger, D., Truong, L., Cummins, L., Owens, S.R., Markham, P.M., Shea, J.P. and Crooke, S. (1993) Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J. Pharmacol. Exp. Ther. 267, 1181-1190.
57. Iverson, P.L., Mata, J., Tracewell, W.G. and Zon, G. (1994) Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion. Antisense Res. Dev. 4, 43-52.
58. Agrawal, S., Temsamani, J. and Tang, J.Y. (1991) Pharmacokinetics, biodistribution and stability of oligodeoxynucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. USA 88, 7595-7599.
59. Goodarzi, G., Watabe, M. and Watabe, K. (1992) Organ distribution and stability of phosphorothioated oligodeoxyribonucLeotides in mice. Biopharm. Drug Dispos. 13, 221-227.
60. 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats. J. Pharmacol. Exp. Ther. 269, 89-94.
61. Wu, G.Y. and Wu, C.H. (1992) Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides. J. Biol. Chem. 267, 12436-12439.
62. Lu, X.M., Fischman, A.J., Jyawook, S., Hendricks, K., Tompkins, R.G. and Yarmush, M.L. (1994) Antisense DNA delivery in vivo: liver targeting by receptor-mediated uptake. J. Nucl. Med. 35, 269-275.
63. Chen, J., Gamou, S., Takayanagi, A. and Shimizu, N. (1994) A novel gene delivery system using EGF receptor-mediated endocytosis. FEBS Lett. 338, 167-169.
64. Wagner, E., Zenke, M., Gotten, M., Beug, H. and Birnstiel, M.L. (1990) Transferrin-polycation conjugates as carriers for DNA uptake into cells. Proc. Natl. Acad. Sci. USA 87, 3410-3414.
65. Citro, G., Perroti, D., Cucco, C., D'Agnano, I., Sacchi, A., Zupi, G. and Calabretta, B. (1992) Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA 89, 7031-7035.
66. Wu, G.Y. and Wu, C.H. (1987) Receptor-mediated in vitro gene transformation by a soluble DNA carrier system. J. Biol. Chem. 10, 4429-4432.
67. Chow, T.Y.K., Juby, C. and Brousseau, R. (1994) Specific targeting of antisense oligonucleotides to neutrophils. Antisense Res. Dev. 4, 81-86.
68. Renneisen, K., Leserman, L., Matthes, E., Schroder, H.C. and Muller, W.E. (1990) Inhibition of expression of human immunodeficiency virus-1 in vito by antibody-targeted liposomes containing antisense RNA to the env region. J. Biol. Chem. 265, 16337-16342.
69. Leonetti, J.P., Machy, P., Degols, G., Lebleu, B. and Leserman, L. (1990) Antibody-targeted liposomes containing oligodeoxyribonucleotides complementary to viral RNA selectively inhibit viral replication. Proc. Natl. Acad. Sci. USA 87, 2448-2451.
70. Nolen III, H.W., Catz, P. and Friend, D.R. (1994) Percutaneous penetration of methyl phosphonate antisense oligonucleotides. Int. J. Pharmaceut. 107, 169-177.
71. Iverson, P. (1991) In vivo studies with phosphorothioate oligonucleotides: pharmacokinetic prologue. Anti-Cancer Drug Design 6, 531-538.
72. Uhlmann, E. and Peyman, A. (1990) Antisense oligonucleotides: a new therapeutic principle. Chem. Rev. 90, 543-584.
73. Woolf, T.M., Jennings, C.G.B., Rebagliati, M. and Melton, D.A. (1990) The stability, toxicity and effectiveness of unmodified and phosphorothioate antisense oligodeoxynucleotides in Xenopus oocytes and embryos. Nucl. Acids Res. 18, 1763-1769.
74. Alper, J. (1993) Oligonucleotides surge into clinical trials. Bio/Technology 11, 1225.
75. Wickstrom, E.L., Bacon, T.A., Gonzalez, A., Freeman, D.L., Lyman, G.H. and Wickstrom, E. (1988) Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxyribonucleotide targeted against c-myc mRNA. Proc. Natl. Acad. Sci. USA 85, 1028-1032.
76. Wu-Pong, S., Weiss, T.L. and Hunt, C.A. (1992) Antisense c-myc oligodeoxyribonucleotide cellular uptake. Pharm. Res. 9, 1010-1017.
77. Miller, P.S., McParland, K.B., Jayaraman, K. and Tso, P.O.P. (1981) Biochemical and biological effects of nonionic nucleic acid methylphosphonates. Biochemistry 20, 1874-1890.
78. Miller, P.S. and Tso, P.O.P. (1987) A new approach to chemotherapy based on molecular biology and nucleic acid chemistry: Matagen (masking tape for gene expression). Anticancer Drug Design 2, 117-128.
79. Letsinger, R.L., Zhang, G., Sun, O.K., Ikeuchi, T. and Sarin, P.S. (1989) Cholesteryl-conjugated oligonucleotides: synthesis, properties and activity as inhibitors of replication of human immunodeficiency virus in cell culture. Proc. Natl. Acad. Sci. USA 86, 6553-6556.
80. Boutorin, A.S., Gus'kova, L.V., Ivanova, E.M., Kobetz, N.D., Zarylova, V.F., Ryte, A.S., Yurchenko, L.V. and Vlassov, V.V. (1989) Synthesis of alykylating oligonucleotide derivatives containing cholesterol or phenazinium residues at their 3′-terminus and their interaction with DNA within mammalian cells. FEBS Lett. 1, 129-132.
81. Lamaitre, M., Bayard, B. and Lebleu, B. (1987) Specific antiviral activity of poly(L-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to vesicular stomatitis virus N protein mRNA initiation site. Proc. Natl. Acad. Sci. USA 84, 648-652.
82. Campos, L., Sabido, O., Rouault, J.P. and Guyotat, D. (1994) Effects of BCL-2 oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemia cells. Blood 84, 595-600.
83. Krieg, A.M., Gmelig-Meyling, F., Gourley, M.F., Kisch, W.J., Chrisey, L.A. and Steinberg, A.D. (1990) Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible. Antisense Res. Dev. 1, 161-171.
84. Noonberg, S.B., Garovoy, M.R. and Hunt, C.A. (1993) Characteristics of oligonucleotide uptake in human keratinocyte cultures. J. Invest. Dermatol. 101, 727-731.
85. Loke, S.L., Stein, C.A., Zhang, X.H., Mori, K., Nakanishi, M., Subasinghe, C., Cohen, J.S. and Neckers, L.M. (1989) Characterization of oligonucleotide transport into living cells. Proc. Natl. Acad. Sci. USA 86, 3474-3478.
86. Shoji, Y., Akhtar, S., Periasamy, A., Herman, B. and Juliano, R.L. (1991) Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages. Nucl. Acids Res. 19, 5543-5550.
87. Stein, C.A., Tonkinson, J.L., Zhang, L.M., Yakubov, L., Gervasoni, J., Taub, R. and Rotenberg, S.A. (1993) Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells. Biochemistry 32, 4855-4861.
88. Yakubov, L.A., Deeva, E.A., Zarytova, V.F., Ivanova, E.M., Ryte, A.S., Yurchenko, L.V. and Vlassov, V.V. (1989) Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? Proc. Natl. Acad. Sci. USA 86, 6454-6458.
89. Wu-Pong, S., Weiss, T.L. and Hunt, C.A. (1994) Cellular uptake and activity of a c-myc antisense oligodeoxribonucleotide. Antisense Res. Dev. 4, 155-163.
90. Wu-Pong, S., Weiss, T.L. and Hunt, C.A. (1994) Calcium-dependent cellular uptake of a c-myc antisense oligonucleotide. Cell. Mol. Biol. 40, 843-850.
91. Leonetti, J.P. and Leserman, L.D. (1993) Targeted delivery of oligonucleotides. In: S.T. Crooke and B. Lebleu (Eds), Antisense Research and Applications, CRC Press, Boca Raton, FL, pp. 493-504.
92. Bennett, C.F., Chiang, M.Y., Chan, H., Shoemaker, J.E.E. and Mirabelli, C.K. (1992) Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 41, 1023-1033.
93. Byron, P.R. (1990) Determinants of drug and polypeptide bioavailability from aerosols delivered to the lung. Adv. Drug Deliv. Rev. 6, 251-270.
94. Byron, P.R. (1986) Some future perspectives for unit dose inhalation aerosols. Drug Dev. Ind. Pharm. 12, 993-1015.
95. Byron, P.R. (1987) Pulmonary targeting with aerosols. Pharm. Tech. 11, 42-56.
96. Byron, P.R., Phillips, E.M. and Kuhn, R. (1988) Ribavirin administration by inhalation: Aerosol generation factors controlling drug delivery to the lung. Resp. Care 33, 1011-1019.
97. Byron, P.R., Dalby, R.N. and Hickey, A.J. (1989) Optimized inhalation aerosols. I. The effects of spherical baffle size and position upon the output of several pressurized nonaqueous suspension formulations. Pharm. Res. 6, 225-229.
98. Chan, T.L. and Lippmann, M. (1980) Experimental measurements and empirical modeling of the regional deposition of inhaled particles in humans. Am. Ind. Hyg. Assoc. J. 41, 399-409.
99. Gerrity, T. (1990) Pathophysiologic and disease constraints on aerosol delivery. In: P.R. Byron (Ed.), Respiratory Drug Delivery, CRC Press, Boca Raton, FL, pp. 1-38.
100. Byron, P.R. (1990) Aerosol formulation, generation and delivery using nonmetered systems. In: P.R. Byron (Ed.), Respiratory Drug Delivery, CRC Press, Boca Raton, FL, pp. 143-165.
101. Byron, P.R. (1986) Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J. Pharm. Sci. 75, 433-438 and 1207-1208.
102. Gonda, I. (1981) A semiempirical model of aerosol deposition in the human respiratory tract for mouth inhalation. J. Pharm. Pharmacol. 33, 692-696.
103. Byron, P.R., Davis, S.S., Bubb, M.D. and Cooper, P. (1977) Pharmaceutical implications of particle growth at high relative humidity. Pest. Sci. 8, 521-526.
104. Gonda, I., Kayes, J.B., Groom, C.V. and Fildes, F.J.T. (1981) Characterization of hygroscopic inhalation aerosols. In: N.G. Stanley-Wood and T. Allen (Eds), Particle Size Analysis, Wiley-Heyden, London, pp. 31-43.
105. Morrow, P.E. (1986) Factors determining hygroscopic aerosol deposition in airways. Physiol. Rev. 66, 330-374.
106. Byron, P.R. (1990) Aerosol formulation, generation and delivery using metered systems. In: P.R. Byron (Ed.), Respiratory Drug Delivery, CRC Press, Boca Raton, FL, pp. 168-205.
107. Hill, M. (1994) Characteristics of an active multiple-dose dry powder inhaler. In: P.R. Byron, R.N. Dalby and S.J. Farr (Eds.), Proceedings of Respiratory Drug Delivery IV, Richmond VA, Interpharm Press, Buffalo Grove, IL, pp. 109-116.
108. Sarin, P.S., Agrawal, S., Civeira, M.P., Goodchild, J., Ikeuchi, T. and Zamecnik, P.C. (1988) Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates. Proc. Natl. Acad. Sci. USA 85, 7448-7451.
109. Zon, G. and Geiser, T.G. (1991) Phosphorothioate oligonucleotides; chemistry, purification, analysis, scale-up and future directions. Anti-Cancer Drug Design 6, 539-568.
110. Sciarra, J.J. and Cutie, A.J. (1986) Pharmaceutical aerosols. In: L. Lachman, L.A. Lieberman and J.L. Kanig (Eds), Theory and Practice of Industrial Pharmacy, 3rd Edn, Lea and Febiger, Philadelphia, PA, pp. 270-294.
111. Shabarova, Z. and Bogdanov, A. (1994) Advanced Organic Chemistry of Nucleic Acids, VCH, Weinheim.
112. Adjei, A. and Garren, J. (1990) Pulmonary delivery of peptide drugs: Effect of particle size on bioavailability of leuprolide acetate in healthy male volunteers. Pharm. Res. 7, 565-569.
113. Townsend, M.W., Byron, P.R. and DeLuca, P.P. (1990) The effects of headspace gas, formulation additives and storage conditions on the degradation of freeze-dried ribonuclease A. Pharm. Res. 7, 1086-1091.
114. Miller, N.C. (1990) Effects of water on metered dose aerosol stability. In: P.R. Byron (Ed.), Respiratory Drug Delivery, CRC Press, Boca Raton, FL, pp. 206-219.
115. Phillips, E.M., Byron, P.R., Fults, K. and Hickey, A.J. (1990) Optimized inhalation aerosols II: Inertial testing methods for aerosol particle size analysis. Pharm. Res. 7, 1228-1233.
116. Phillips, E.M. and Byron, P.R. (1994) Surfactant promoted crystal growth of micronized methylprednisolone in trichloromonofluoromethane. Int. J. Pharm. 110, 9-19.
117. Byron, P.R. (1994) Dosing reproducibility from experimental albuterol suspension metered dose inhalers. Pharm. Res. 11, 580-584.
118. Jashnani, R.N., Byron, P.R. and Dalby, R.N. (1995) Testing of dry powder aerosol formulations in different environmental conditions. Int. J. Pharm. 113, 123-130.
119. Gonda, I. and Byron, P.R. (1978) Perspectives on the biopharmacy of inhalation aerosols. Drug Dev. Ind. Pharm. 4, 243-259.
120. Crooks, P.A. and Damani, L.A. (1990) Drug application to the respiratory tract: metabolic and pharmacokinetic considerations. In: P.R. Byron (Ed.), Respiratory Drug Delivery, CRC Press, Boca Raton, FL, pp. 62-90.
121. Byron, P.R. (1993) Physicochemical effects on lung disposition of pharmaceutical aerosols. Aerosol Sci. Technol. 18, 223-229.
122. Wangensteen, D. (1991) Microstructural aspects of macromolecular transport across pulmonary epithelium. Proceedings of Respiratory Drug Delivery II, Keystone CO, University of Kentucky, pp. 117-140.
123. Byron, P.R. and Phillips, E.M. (1990) Absorption, clearance and dissolution in the lung. In: P.R. Byron (Ed.), Respiratory Drug Delivery, CRC Press, Boca Raton, FL, pp. 108-141.
124. Colthorpe, P., Farr, S.J., Taylor, G., Smith, I.J. and Wyatt, D. (1992) The pharmacokinetics of pulmonary delivered insulin: a comparison of intratracheal and aerosol administration to the rabbit. Pharm. Res. 9, 764-768.
125. Byron, P.R., Sun, Z., Katayama, H. and Rypacek, F. (1994) Solute absorption from the airways of the isolated rat lung IV: Mechanism of dose dependent absorption of fluorophore-labeled poly a,b-[N-(2-hydroxyethyl)-DL-aspartamide]. Pharm. Res. 11, 221-225.
126. Patton, J.S. and Platz, R.M. (1992) Routes of delivery: Case studies (2): pulmonary delivery of peptides and proteins for systemic action. Adv. Drug Deliv. Rev. 8, 179-196.
127. Patton, J.S., Trinchero, P. and Platz, R.M. (1994) Bioavailability of pulmonary delivered peptides and proteins: Interferon alpha, calcitonins and parathyroid hormones. J. Control. Release 28, 79-85.
128. Niven, R.W. and Byron, P.R. (1990) Solute absorption from the airways of the isolated rat lung. II. Effect of surfactants on fluorescein absorption. Pharm. Res. 7, 8-13.
129. Schanker, L.S. and Hemberger, J.A. (1983) Relation between molecular weight and pulmonary absorption rate of lipid insoluble compounds in neonatal and adult rats. Biochem. Pharmacol. 32, 2599-2601.
130. Lo, S.K., Everitt, J., Gu, J. and Malik, A.B. (1992) Tumor necrosis factor mediates experimental pulmonary edema by ICAM-1 and CD 18-dependent mechanisms. J. Clin. Invest. 89, 981-988.
131. Dustin, M.L. and Springer, T.A. (1988) Lymphocyte function associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. J. Cell Biol. 107, 321-331.
132. Hill, P.A., Lan, H.Y., Nikolok-Paterson, D.J. and Atkins, R.C. (1994) Pulmonary expression of ICAM-1 and LFA-1 in experimental Goodpasture's syndrome. Am. J. Pathol. 145, 220-227.
133. Osborne, L. (1990) Leukocyte adhesion to endothelium in inflammation. Cell 56, 907-910.
134. Springer, T.A. (1990) Adhesion receptors of the immune system. Nature 346, 425-443.
135. Hollinger, M.A. (1985) Respiratory Pharmacology and Toxicology, W.B. Saunders, Philadelphia, PA, pp. 1-20.
136. Legendre, J.-Y. and Szoka, F.C. Jr (1992) Delivery of plasmid DNA into mammalian cell lines using pH-sensitive liposomes: comparison with cationic liposomes. Pharm. Res. 9, 1235-1242.
137. Behr, J.-P., Demeneix, B., Loeffler, J.-P. and Perez-Mutul, J. (1989) Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA. Proc. Natl. Acad. Sci. USA 86, 6982-6986.
138. Wiener-Kronish, J.P. (1994) The delivery of genes to the lung. Proceedings of Respiratory Drug Delivery IV, Richmond VA, In: P.R. Byron, R.N. Dalby and S.J. Farr (Eds), Interpharm Press, Buffalo Grove, IL, pp. 11-18.
139. Logan, J.J., Bebok, Z., Walker, L.C., Peng, S., Felgner, P.L., Siegal, O.P., Frizzell, R.A., Dong, J., Howard, M., Matalon, S., Lindsey, J.R., Duvall, M. and Sorscher, E.J. (1995) Cationic lipids for reporter gene and CFTR transfer to rat pulmonary epithelium. Gene Ther. 2, 38-49.
140. Mirabelli, C.K., Benner, C.F., Anderson, K. and Crooke, S.T. (1991) In vitro and in vivo pharmacologic activities of antisense oligonucleotides. Anticancer Drug Design 6, 647-661.